Mira Pharma Financials
This page shows Mira Pharma (MIRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MIRA’s visible operating mechanic is cash burn funded by equity issuance, while the balance sheet remains lightly leveraged.
From FY2024 to FY2025, cash climbed from$2.83M to$6.35M even though operations were still consuming cash, so the stronger liquidity did not come from the business becoming self-funding. The funding was equity-led, not operational: financing cash flow was$8.18M , and shares outstanding more than doubled, which means cash runway improved alongside meaningful dilution.
FY2025 showed a cost-mix shift: SG&A rose to
Balance-sheet pressure is not coming from lenders: liabilities were
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Mira Pharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Mira Pharma carries a low D/E ratio of 0.07, meaning only $0.07 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 15.75, Mira Pharma holds $15.75 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Mira Pharma generates a -100.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -357.0% the prior year.
Mira Pharma passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Mira Pharma generates $0.45 in operating cash flow (-$4.7M OCF vs -$10.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Mira Pharma reported -$10.4M in net income in fiscal year 2025. This represents a decrease of 33.0% from the prior year.
Mira Pharma earned $-1.35 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 164.7% from the prior year.
Cash & Balance Sheet
Mira Pharma held $6.3M in cash against $0 in long-term debt as of fiscal year 2025.
Mira Pharma had 42M shares outstanding in fiscal year 2025. This represents an increase of 153.2% from the prior year.
Margins & Returns
Mira Pharma's ROE was -100.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 256.5 percentage points from the prior year.
Capital Allocation
Mira Pharma invested $1.7M in research and development in fiscal year 2025. This represents a decrease of 48.0% from the prior year.
MIRA Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $525K | N/A | $413K-16.8% | $496K+57.8% | $314K | N/A | $1.1M+73.7% | $614K |
| SG&A Expenses | $579K | N/A | $904K-13.9% | $1.0M-29.6% | $1.5M | N/A | $1.0M-9.1% | $1.1M |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $45K | N/A | $16K | N/A | -$21K | N/A | -$38K+4.2% | -$39K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.2M | N/A | -$1.1M+26.0% | -$1.5M+13.8% | -$1.8M | N/A | -$2.0M-20.8% | -$1.7M |
| EPS (Diluted) | $-0.03 | N/A | $-1.18-1211.1% | $-0.09+18.2% | $-0.11 | N/A | $-0.14-27.3% | $-0.11 |
MIRA Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.5M-14.7% | $11.1M+45.3% | $7.6M+779.1% | $868K-38.0% | $1.4M-52.1% | $2.9M-31.5% | $4.3M+41.5% | $3.0M |
| Current Assets | $9.4M-14.7% | $11.1M+45.5% | $7.6M+812.2% | $833K-39.0% | $1.4M-52.7% | $2.9M-31.8% | $4.2M+44.3% | $2.9M |
| Cash & Equivalents | $4.8M-24.1% | $6.3M+140.3% | $2.6M+261.6% | $730K-39.4% | $1.2M-57.4% | $2.8M-31.6% | $4.1M+46.8% | $2.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $5K | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $115K-83.7% | $702K+736.5% | $84K-71.9% | $298K+181.1% | $106K-85.3% | $723K+4.4% | $693K-13.0% | $797K |
| Current Liabilities | $115K-83.7% | $702K+736.5% | $84K-71.9% | $298K+181.1% | $106K-85.3% | $723K+4.4% | $693K-13.0% | $797K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.3M-10.0% | $10.4M+37.6% | $7.5M+1224.8% | $570K-56.0% | $1.3M-41.2% | $2.2M-38.4% | $3.6M+61.1% | $2.2M |
| Retained Earnings | -$40.7M-2.9% | -$39.6M-17.8% | -$33.6M-3.5% | -$32.5M-5.0% | -$30.9M-6.1% | -$29.1M-9.0% | -$26.7M-8.3% | -$24.7M |
MIRA Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M-5.8% | -$1.1M-3.5% | -$1.1M-37.2% | -$800K+50.9% | -$1.6M+9.7% | -$1.8M+2.0% | -$1.8M-113.2% | -$864K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$331K-106.8% | $4.8M+60.9% | $3.0M+828.9% | $324K+9478.3% | $3K-99.3% | $493K-84.4% | $3.2M+1889.1% | $159K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MIRA Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -12.3% | N/A | -15.1%+254.8pp | -269.8%-132.0pp | -137.8% | N/A | -57.2%+19.0pp | -76.2% |
| Return on Assets | -12.2% | N/A | -14.9%+162.2pp | -177.1%-49.7pp | -127.4% | N/A | -47.9%+8.2pp | -56.1% |
| Current Ratio | 82.16+66.4 | 15.75-74.8 | 90.53+87.7 | 2.79-10.1 | 12.86+8.9 | 3.99-2.1 | 6.11+2.4 | 3.68 |
| Debt-to-Equity | 0.01-0.1 | 0.07+0.1 | 0.01-0.5 | 0.52+0.4 | 0.08-0.2 | 0.33+0.1 | 0.19-0.2 | 0.36 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Mira Pharma profitable?
No, Mira Pharma (MIRA) reported a net income of -$10.4M in fiscal year 2025.
What is Mira Pharma's return on equity (ROE)?
Mira Pharma (MIRA) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mira Pharma's operating cash flow?
Mira Pharma (MIRA) generated -$4.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Mira Pharma's total assets?
Mira Pharma (MIRA) had $11.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Mira Pharma spend on research and development?
Mira Pharma (MIRA) invested $1.7M in research and development during fiscal year 2025.
What is Mira Pharma's current ratio?
Mira Pharma (MIRA) had a current ratio of 15.75 as of fiscal year 2025, which is generally considered healthy.
What is Mira Pharma's debt-to-equity ratio?
Mira Pharma (MIRA) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mira Pharma's return on assets (ROA)?
Mira Pharma (MIRA) had a return on assets of -94.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Mira Pharma's cash runway?
Based on fiscal year 2025 data, Mira Pharma (MIRA) had $6.3M in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Mira Pharma's Piotroski F-Score?
Mira Pharma (MIRA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mira Pharma's earnings high quality?
Mira Pharma (MIRA) has an earnings quality ratio of 0.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Mira Pharma?
Mira Pharma (MIRA) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.